196 related articles for article (PubMed ID: 28800130)
21. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
Xu S; Fu GB; Tao Z; OuYang J; Kong F; Jiang BH; Wan X; Chen K
Oncotarget; 2015 Sep; 6(28):26457-71. PubMed ID: 26238185
[TBL] [Abstract][Full Text] [Related]
22. Long non-coding RNA ZFAS1 interacts with miR-150-5p to regulate Sp1 expression and ovarian cancer cell malignancy.
Xia B; Hou Y; Chen H; Yang S; Liu T; Lin M; Lou G
Oncotarget; 2017 Mar; 8(12):19534-19546. PubMed ID: 28099946
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA-495 Regulates Migration and Invasion in Prostate Cancer Cells Via Targeting Akt and mTOR Signaling.
Li JZ; Wang ZL; Xu WH; Li Q; Gao L; Wang ZM
Cancer Invest; 2016; 34(4):181-8. PubMed ID: 27031291
[TBL] [Abstract][Full Text] [Related]
24. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.
Creighton CJ; Fountain MD; Yu Z; Nagaraja AK; Zhu H; Khan M; Olokpa E; Zariff A; Gunaratne PH; Matzuk MM; Anderson ML
Cancer Res; 2010 Mar; 70(5):1906-15. PubMed ID: 20179198
[TBL] [Abstract][Full Text] [Related]
25. Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells.
Báez-Vega PM; Echevarría Vargas IM; Valiyeva F; Encarnación-Rosado J; Roman A; Flores J; Marcos-Martínez MJ; Vivas-Mejía PE
Oncotarget; 2016 Jun; 7(24):36321-36337. PubMed ID: 27166999
[TBL] [Abstract][Full Text] [Related]
26. Multiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers.
Ciucci A; Zannoni GF; Buttarelli M; Lisi L; Travaglia D; Martinelli E; Scambia G; Gallo D
Oncotarget; 2016 Feb; 7(7):8155-71. PubMed ID: 26797759
[TBL] [Abstract][Full Text] [Related]
27. In vivo tumor growth of high-grade serous ovarian cancer cell lines.
Mitra AK; Davis DA; Tomar S; Roy L; Gurler H; Xie J; Lantvit DD; Cardenas H; Fang F; Liu Y; Loughran E; Yang J; Sharon Stack M; Emerson RE; Cowden Dahl KD; V Barbolina M; Nephew KP; Matei D; Burdette JE
Gynecol Oncol; 2015 Aug; 138(2):372-7. PubMed ID: 26050922
[TBL] [Abstract][Full Text] [Related]
28. FBLN5 is targeted by microRNA‑27a‑3p and suppresses tumorigenesis and progression in high‑grade serous ovarian carcinoma.
Li R; Wu H; Jiang H; Wang Q; Dou Z; Ma H; Yan S; Yuan C; Yang N; Kong B
Oncol Rep; 2020 Nov; 44(5):2143-2151. PubMed ID: 32901854
[TBL] [Abstract][Full Text] [Related]
29. Pancreas-specific activation of mTOR and loss of p53 induce tumors reminiscent of acinar cell carcinoma.
Kong B; Cheng T; Qian C; Wu W; Steiger K; Cao J; Schlitter AM; Regel I; Raulefs S; Friess H; Erkan M; Esposito I; Kleeff J; Michalski CW
Mol Cancer; 2015 Dec; 14():212. PubMed ID: 26683340
[TBL] [Abstract][Full Text] [Related]
30. miR-199a-3p is involved in estrogen-mediated autophagy through the IGF-1/mTOR pathway in osteocyte-like MLO-Y4 cells.
Fu J; Hao L; Tian Y; Liu Y; Gu Y; Wu J
J Cell Physiol; 2018 Mar; 233(3):2292-2303. PubMed ID: 28708244
[TBL] [Abstract][Full Text] [Related]
31. Modulation of TSC-mTOR signaling on immune cells in immunity and autoimmunity.
Yang H; Wang X; Zhang Y; Liu H; Liao J; Shao K; Chu Y; Liu G
J Cell Physiol; 2014 Jan; 229(1):17-26. PubMed ID: 23804073
[TBL] [Abstract][Full Text] [Related]
32. Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.
Lee YJ; Kim D; Shim JE; Bae SJ; Jung YJ; Kim S; Lee H; Kim SH; Jo SB; Lee JY; Kim HS; Paik S
Int J Cancer; 2020 Apr; 146(7):1851-1861. PubMed ID: 31603993
[TBL] [Abstract][Full Text] [Related]
33. Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts.
Todeschini P; Salviato E; Paracchini L; Ferracin M; Petrillo M; Zanotti L; Tognon G; Gambino A; Calura E; Caratti G; Martini P; Beltrame L; Maragoni L; Gallo D; Odicino FE; Sartori E; Scambia G; Negrini M; Ravaggi A; D'Incalci M; Marchini S; Bignotti E; Romualdi C
Cancer Lett; 2017 Mar; 388():320-327. PubMed ID: 28017893
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-κB signaling pathway.
Ren D; Yang Q; Dai Y; Guo W; Du H; Song L; Peng X
Mol Cancer; 2017 Jul; 16(1):117. PubMed ID: 28693582
[TBL] [Abstract][Full Text] [Related]
35. Pivotal role of augmented αB-crystallin in tumor development induced by deficient TSC1/2 complex.
Wang F; Chen X; Li C; Sun Q; Chen Y; Wang Y; Peng H; Liu Z; Chen R; Liu K; Yan H; Ye BH; Kwiatkowski DJ; Zhang H
Oncogene; 2014 Aug; 33(34):4352-8. PubMed ID: 24077282
[TBL] [Abstract][Full Text] [Related]
36. NF-κB mediated miR-130a modulation in lung microvascular cell remodeling: Implication in pulmonary hypertension.
Li L; Kim IK; Chiasson V; Chatterjee P; Gupta S
Exp Cell Res; 2017 Oct; 359(1):235-242. PubMed ID: 28755990
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA expression profiles in serous ovarian carcinoma.
Nam EJ; Yoon H; Kim SW; Kim H; Kim YT; Kim JH; Kim JW; Kim S
Clin Cancer Res; 2008 May; 14(9):2690-5. PubMed ID: 18451233
[TBL] [Abstract][Full Text] [Related]
38. Immunostaining Study on the Expression of NF-κB, ER, and PR in Ovarian Serous Carcinoma.
Lin J; Xi C; Liu C; Wang Y; Liu Y; Ren C; Liu C
Int J Gynecol Pathol; 2017 Jan; 36(1):58-63. PubMed ID: 27171541
[TBL] [Abstract][Full Text] [Related]
39. Propofol inhibits invasion and growth of ovarian cancer cells via regulating miR-9/NF-κB signal.
Huang X; Teng Y; Yang H; Ma J
Braz J Med Biol Res; 2016 Dec; 49(12):e5717. PubMed ID: 27982283
[TBL] [Abstract][Full Text] [Related]
40. High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
Li M; Cheng X; Rong R; Gao Y; Tang X; Chen Y
BMC Cancer; 2020 Oct; 20(1):1032. PubMed ID: 33109151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
